You may consider a type of nebulizer for your COPD treatment. These small devices convert medications into mist, allowing you to breathe them in more easily through a mask or machine. The most ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic obstructive ...

Verona Pharma reported a total of $36 million in net revenue for the fourth quarter of 2024, solely attributed to sales of Ohtuvayre (ensifentrine), its FDA-approved treatment for chronic ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Medicare classifies nebulizers as durable medical equipment (DME), which is covered by Part B. A person must have a prescription, while other rules and out-of-pocket expenses may apply.

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other ...

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term benefits by reducing the rate of exacerbations over a 24-week period. The ...

Firstly, as per the report of the third quarter of 2024, significant financial growth was seen as the net sales reported were $5.6 million, largely due to product sales of Ohtuvayre. Secondly, ...

Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients in more than 20 years.